1. Home
  2. INLX vs JSPR Comparison

INLX vs JSPR Comparison

Compare INLX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

BUY

Current Price

$4.58

Market Cap

21.6M

Sector

Technology

ML Signal

BUY

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.50

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
JSPR
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
26.3M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
INLX
JSPR
Price
$4.58
$0.50
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $6.38
AVG Volume (30 Days)
24.2K
★ 376.2K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 19.22
EPS
N/A
★ N/A
Revenue
★ $11,336.00
N/A
Revenue This Year
$14.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.12
$0.32
52 Week High
$10.33
$2.51

Technical Indicators

Market Signals
Indicator
INLX
JSPR
Relative Strength Index (RSI) 43.11 38.88
Support Level N/A $0.42
Resistance Level $6.00 $0.67
Average True Range (ATR) 0.93 0.05
MACD -0.01 -0.00
Stochastic Oscillator 17.00 25.07

Price Performance

Historical Comparison
INLX
JSPR

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: